In 1992 in El product Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis for and migraines in 1992-1993 was conducted. product and for The migraines average IgE level of the placebo treated subjects remained essentially product flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, for one year after the first set of symptom diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts migraines at the study site in 1993 were much higher than in 1992, leading to expectation product of higher symptoms.)7

Genentech and Novartis are developing an anti-IgE monoclonal antibody for asthma and allergic rhinitis. In December 1999 they announced for positive study results. This is evidence that reducing IgE results in a reduction of symptoms associated with IgE-mediated allergic disease.13 migraines For product people who find they cannot for adequately avoid the allergens, the symptoms often can be controlled with medications. Effective medications that can be prescribed by a physician include antihistamines, topical nasal steroids, and cromolyn sodium migraines - any product of which can be used alone or in combination. Many effective for antihistamines and decongestants also are available without a prescription. migraines Click here for allergy medication online.